A Review of Vinorelbine in the Treatment of Advanced Breast Cancer

• Published in: Clinical Medicine Insights: Therapeutics Vol. 2009; no. 1; p. 1715
• Main Authors: Brunello, A., Roma, A., Basso, U., Jirillo, A.
• Format: Journal Article Book Review
• Language: English
• Published: London, England SAGE Publishing 01.01.2009; SAGE Publications; Sage Publications Ltd
• Subjects: Breast cancer; vinorelbine; trastuzumab; oral; advanced breast cancer; vinca alkaloid
• ISSN: 1179-559X; 1179-1713; 1179-559X; 1179-1713
• DOI: 10.4137/CMT.S1153

A. Brunello, A. Roma, U. Basso and A. JirilloIstituto Oncologico Veneto, Division of Medical Oncology, 35126 Padova, Italy.AbstractVinorelbine is a semi-synthetic vinca alkaloid that has been shown active in many tumor types and is currently registered for the treatment of advanced breast cancer (ABC) and non-small cell lung cancer (NSCLC), and it is used in other cancer type such as prostate cancer, lymphomas, gynecologic malignancies. This agent has a generally favorable safety profile, and may be suitable for use in special populations such as the elderly and/or frail patient. However, with the taxanes established as standard second line treatment for ABC after failure of an anthracycline, Vinorelbine has been generally relegated for use as third line therapy, in competition with the oral compound Capecitabine. Combination regimens of Vinorelbine and Gemcitabine have been indeed widely studied, and have been demonstrated to be safe and effective. More recently, the exciting results observed with the combination of Vinorelbine and Trastuzumab in patients with Her-2 overexpressing tumors, as well as the development of a reliable formulation and revised schedule of oral Vinorelbine appear to have revived the interest in this compound in the management of this disease. Yet, data from properly designed randomized clinical trials are eagerly awaited to confirm the amount of available data which are mostly based on phase II studies.